OLX-07010 for Alzheimer's Disease Prevention
Trial Summary
What is the purpose of this trial?
This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults (18-50 of age inclusive), and single dose in healthy elderly (51-75 of age inclusive). The effects of dosing with or without food in healthy adults will also be studied (optional).
Eligibility Criteria
Healthy adults aged 18-50 and healthy elderly individuals aged 51-75, all of non-childbearing potential, can participate. They must have a stable weight within certain BMI ranges and no significant medical history or current conditions that could affect the study drug's processing in the body.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Single Ascending Dose (SAD)
Participants receive single ascending doses of OLX-07010 to evaluate safety, tolerability, and pharmacokinetics
Multiple Ascending Dose (MAD)
Participants receive multiple ascending doses of OLX-07010 to evaluate safety, tolerability, and pharmacokinetics
Food Effect Study (Optional)
Participants receive OLX-07010 with and without food to evaluate the effect of food on drug pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- OLX-07010
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oligomerix, Inc
Lead Sponsor